CD28 and neoplasm: A long list of studies employing CARs with a CD28 signaling domain reported potent and quick anti-tumor effector functions but found these to be rather short-lived and associated with limited cell persistence in vivo when compared to, e.g., the 4-1BB signaling domain [113,143,145,146].